BI-671800

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H26F3N5O3
Molecular Weight	501.5008
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1=NC(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)=NC(N(C)C)=C1CC(O)=O

InChI

InChIKey=XEOSTBFUCNZKGS-UHFFFAOYSA-N

InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)

HIDE SMILES / InChI

Molecular Formula	C25H26F3N5O3
Molecular Weight	501.5008
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25861737
Curator's Comment: Description was created based on several sources, including http://erj.ersjournals.com/content/40/Suppl_56/P1792

Boehringer Ingelheim is developing BI-671800, an orally administered treatment for seasonal allergic rhinitis and asthma. BI-671800 is an antagonist of the PGD2 receptor, CRTH2. PGD2 stimulates bronchoconstriction and allergic airway inflammation in animal models. Inhibition of CRTH2 may reduce airway inflammatory cells, IL -4, -5, -13 production, serum IgE and airway hyper reactivity. Treatment with BI-671800 in poorly controlled asthmatic patients receiving FP was associated with a significant improvement in FEV1. BI-671800 was well tolerated at a total daily dose of 800 mg for 6 weeks.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
G protein-coupled receptor 44 7 Target ID: CHEMBL5071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25861737 \| http://adisinsight.springer.com/drugs/800031233	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Seasonal allergic rhinitis 64 Sources: https://clinicaltrials.gov/ct2/show/NCT01007721 http://adisinsight.springer.com/drugs/800031233	Primary		Phase II 1147	Unknown Approved Use Unknown
Asthma 244 Sources: https://clinicaltrials.gov/ct2/show/NCT01090024 http://adisinsight.springer.com/drugs/800031233	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
7600 ng/mL OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4780 ng/mL OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32500 ng × h/mL OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
19100 ng × h/mL OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.2 h OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.05 h OTHER GOV'T https://www.mystudywindow.com/trial/completed/253367/1268-0059	200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BI-671800 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
Chem Scene	CS-0070031	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0070031
ChemShuttle	140456	https://www.chemshuttle.com/catalogsearch/result/?q=140456
eMolecules	222564490	https://orderbb.emolecules.com/search/#?query=222564490
Hangzhou APIChem Technology	AC-30903
MedChem Express	HY-114141	https://www.medchemexpress.com/search.html?q=HY-114141&ft=&fa=&fp=
MolPort	MolPort-046-683-365	https://www.molport.com/shop/molecule-link/MolPort-046-683-365
MuseChem	I004211	https://www.musechem.com/product/I004211.html

PubMed

Title	Date	PubMed
Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation.	2016-10	27453494
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.	2015-06	25861737
Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.	2014-02	24332218

Patents

Sample Use Guides

In Vivo Use Guide

Oral BI-671800 ED 200 mg twice daily or 400 mg once daily administered in the morning (AM) or evening (PM), in symptomatic asthma patients

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:20:37 GMT 2025` Edited by `admin` on `Mon Mar 31 18:20:37 GMT 2025`
Record UNII	721F767LHB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BI671800

Preferred Name

English

BI-671800

Code

English

5-PYRIMIDINEACETIC ACID, 4,6-BIS(DIMETHYLAMINO)-2-((4-((4-(TRIFLUOROMETHYL)BENZOYL)AMINO)PHENYL)METHYL)-

Common Name

English

Code System Code Type Description

DRUG BANK

DB12524